Raccourcis investisseurs

Publications clefs

• Carvelli, Demaria, Vély, Batista, Chouaki Benmansour, Fares, Carpentier, Thibult, Morel, Remark, André, Represa, Piperoglou, Cordier, Le Dault, Guervilly, Simeone, Gainnier, Ebbo, Schleinitz, Vivier et al, 2020. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis Nature
• Demaria et al, 2019. Harnessing innate immunity in cancer therapy Nature
• Pr Martine Bagot et al, 2019. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial The Lancet Oncology
• Laurent Gauthier et al, 2019. Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity Cell
• Ivan Perrot et al, 2019. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies Cell Reports
• André, Vivier et al, 2018. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells Cell
• Chiossone et al, 2018. Natural killer cells and other innate lymphoid cells in cancer Nat Rev Immunol.

Webcasts majeurs

• ICML 2019: IPH4102 TELLOMAK KOL call > see
• ASH 2018: Updated results on IPH4102 > see
• ESMO 2018: Phase II trial of monalizumab and cetuximab > see
• Expansion of oncology development collaboration with AstraZeneca (October 23th, 2018)  > see